Eyam Vaccines and Immunotherapeutics (EYAM) today announced that a License Agreement has been reached between the University of British Columbia (UBC) and EYAM for the commercialization of several unique COVID-19 vaccine candidates developed at UBC. This License Agreement represents an important corporate milestone.

Eyam Vaccines and Immunotherapeutics (EYAM) today announced that former President and CEO of Genome Prairie is joining EYAM.

Stephen Barr needed reagents in his quest to develop a vaccine for SARS-CoV-2, the virus that causes COVID-19...